Neprilysin as heart failure prognostic marker
AssigneeFundació Institut D'Investigació En CièNcies De La Salut Germans Trias I Pujol
InventorsAntoni Bayes Genis, Josep Lupón Rosés, Amparo Galán Ortega, Jaume Barallat Martínez De Osaba
Life of this patent
Estimating the term…
Abstract
The present invention provides an in vitro method for determining the prognosis in a patient suffering a heart failure disease, the method comprising the step of determining the level of soluble neprilysin (NEP) in a test sample of the patient.
Claims13
An in vitro method for determining the prognosis in a patient suffering a heart failure disease (HF), the method comprising the step of determining the level of soluble neprilysin (NEP) in a test sample of the patient.
A method of deciding or recommending to initiate a medical regimen based on NEP inhibitors in a subject suffering a heart failure disease, which method comprises the steps of (a) determining, in vitro, the amount of soluble NEP in a test sample of the subject;
- and (b) comparing the amount obtained in step (a) with a reference value, wherein if the amount of soluble NEP detected in step (a) is higher than the reference value it is indicative that the subject would benefit from a medical regimen based on NEP inhibitors.
Dependencies are inferred from the claim text.